Давид Хаят - Антираковая диета. Продукты, которые мы должны есть, чтобы защититься от опасного недуга

{30} Seeni A., Takahashi S., Takeshita K., Tang M., Sugiura S., Sato S. Y., Shirai T., «Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model», Asian Pac. J. Cancer Prev., 2008, 9 (1), p. 7—14.

{31} Sengottuvelan M., Deeptha K., Nalini N., «Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazineinduced colon carcinogenesis», Nutrition, 2009, 25 (11–12), p. 1169–1176.

{32} Ding X. Z., Adrian T. E., «Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells», Pancreas, 2002, 25 (4), p. 71–76.

{33} Woodall C. E., Li Y., Liu Q. H., Wo J., Martin R. C., «Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation», Anticancer Drugs, 2009, 20 (6), p. 437–443.

{34} AFSSA, «Table CIQUAL 2008», op. cit.

{35} Direction générale de la Santé, Cancer de la peau. Mélanome, 2003. Disponible sur: http://www.sante.gouv.fr/htm/dossiers/losp/34cancer_ peau.pdf (consulté le 18 mars 2010).

{36} AFSSET, FAQ Rayonnement ultraviolet. Disponible sur: http:// www.afsset.fr/index.php?pageid=634 & parentid=265&ongletlstid=427 (consulté le 17 mars 2010).

{37} Sayre R. M., Dowdy J. C., «The increase in melanoma: are dietary furocoumarins responsable?», Med Hypotheses , 2008, 70 (4), p. 855–859.

{38} Feskanich D., Willett W. C., Hunter D. J., Colditz G. A., «Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women», Br. J. Cancer, 2003, 88 (9), p. 1381–1387.

{39} Malik A., Afaq F., Sarfaraz S., Adhami V. M., Syed D. N., Mukhtar H., «Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer», Proc. Natl. Acad. Sci., 2005, 102 (41), p. 14813—14818.

{40} Pantuck A. J., Leppert J. T., Zomorodian N., Aronson W., Hong J., Barnard R. J., Seeram N., Liker H., Wang H., Elashoff R., Heber D., Aviram M., Ignarro L., Belldegrun A., «Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer», Clin. Cancer Res., 2006, 12 (13), p. 4018–4026.

{41} Zhang Y., Seeram N. P., Heber D., Chen S., Adams L. S., «Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro », Cancer Prev. Res. (Phila Pa), 2010, 3 (1), p. 108–113.

{42} Khan G. N., Gorin M. A., Rosenthal D., Pan Q., Bao L. W., Wu Z. F., Newman R. A., Pawlus A. D., Yang P., Lansky E. P., Merajver S. D., «Pomegranate fruit extract impairs invasion and motility in human breast cancer», Integr. Cancer Ther., 2009, 8 (3), p. 242–253.

{43} Seeram N. P. et al., «In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice», J. Nutr. Biochem., 2005, 16 (6), p. 360–367.

{44} Gil M. I., Tomâs-Barberân F. A., Hess-Pierce B., Holcroft D. M., Kader A. A., «Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing», J. Agric. Food Chem., 2000, 48 (10), p. 4581–4589.

{45} Khan N., Afaq F., Kweon M. H., Kim K., Mukhtar H., «Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice», Cancer Res, 2007, 67 (7), p. 3475–3482.

{46} Gil M. I., Tomâs-Barberân F. A., Hess-Pierce B., Holcroft D. M., Kader A. A., «Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing», op. cit.

{47} Khan N., Afaq F., Kweon M. H., Kim K., Mukhtar H. «Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice», Cancer Res, 2007, 67 (7), p. 3475–3482.

{48} Pantuck A. J., Leppert J. T., Zomorodian N., Aronson W., Hong J., Barnard R. J., Seeram N., Liker H., Wang H., Elashoff R., Heber D., Aviram M., Ignarro L., Belldegrun A., «Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer», Clin. Cancer Res., 2006, 2 (13), p. 4018–4026.

{49} Gil M. I., Tomâs-Barberân F. A., Hess-Pierce B., Holcroft D. M., Kader A. A., «Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing», op. cit.

{50} MacMahon B., Yen S., Trichopoulos D., Warren K., Nardi G. «Coffee and cancer of the pancreas», N. Engl. J. Med., 1981, 304 (11), p. 630–633.

{51} Nkondjock A., «Coffee consumption and the risk of cancer: An overview», Cancer Lett., 2008, 277 (2), p. 121–125.

{52} World Cancer Research Fund, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, op. cit.

{53} Pelucchi C., Tavani A., La Vecchia C., «Coffee and alcohol consumption and bladder cancer», Scand. J. Urol. Nephrol., 2008, 218, suppl., p. 37–44.

{54} Baker J. A., Beehler G. P., Sawant A. C., Jayaprakash V., Mc-Cann S. E., Moysich K. B., «Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer», J. Nutr., 2006, 136 (1), p. 166–171.

{55} Nkondjock A., Ghadirian P., Kotsopoulos J., Lubinski J., Lynch H., Kim Sing C., Horsman D., Rosen B., Isaacs C., Weber B., Foulkes W., Ainsworth P., Tung N., Eisen A., Friedman E., Eng C., Sun P., Narod S. A., «Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers», Int. J. Cancer, 2006, 118 (1), p. 103–107.

{56} Shanafelt T. D., Lee Y. K., Call T. G., Nowakowski G. S., Dingli D., Zent C. S., Kay N. E., «Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies», Leuk. Res., 2006, 30 (6), p. 707–712.

{57} Tsao A. S., Liu D., Martin J., Tang X. M., Lee J. J., El-Naggar A. K., Wistuba I., Culotta K. S., Mao L., Gillenwater A., Sagesaka Y. M., Hong W. K., Papadimitrakopoulou V., «Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions», Cancer Prev. Res. (Phila Pa), 2009, 2 (11), p. 931–941.

{58} Tsao A. S., Liu D., Martin J., Tang X. M., Lee J. J., El-Naggar A. K., Wistuba I., Culotta K. S., Mao L., Gillenwater A., Sagesaka Y. M., Hong W. K., Papadimitrakopoulou V., «Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions», op. cit.

{59} World Cancer Research Fund, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, op. cit.

{1} Vidal, Le Guide Vidal des compléments alimentaires disponible en librairie, Communiqué de Presse, 2010. Disponible sur: http://www. vidal.fr/presse/espace-grand-public/363-guide-complements-alimentaires (consulté le 15 mars 2010).

{2} AFSSA, Etude individuelle nationale des consommations alimentaires 2 (INCA 2) 2006–2007, 2009. Disponible sur: http://www.afssa.fr/ Documents/PASER-Ra-INCA2.pdf (consulté le 15 mars 2010).

{3} Ferrucci L. M., McCorkle R., Smith T., Stein K. D., Cartmel B., «Factors related to the use of dietary supplements by cancer survivors», J. Altern. Complement. Med., 2009, 15 (6), p. 673–680.

{4} Cassileth B. R., Heitzer M., Wesa K., «The public health impact of herbs and nutritional supplements», Pharm. Biol., 2009, 47 (8), p. 761–767.

{5} Kimura Y., Ito H., Ohnishi R., Hatano T., «Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity», Food Chem. Toxicol., 2009, 48 (1), p. 429–435.

{6} Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Meyskens F. L. Jr, Omenn G. S., Valanis B., Williams J. H. Jr., «The beta-carotene and retinol efficacy trial: Incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements», J. Natl. Cancer Inst., 2004, 96 (23), p. 1743–1750.

{7} Virtamo J., Pietinen P., Huttunen J. K., Korhonen P., Malila N., Virtanen M. J., Albanes D., Taylor P. R., Albert P., ATBC Study Group, «Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: A postintervention follow-up», JAMA, 2003, 290 (4), p. 476–485.

{8} Cook N. R., Le I. M., Manson J. E., Buring J. E., Hennekens C. H., «Effects of beta-carotene supplementation on cancer Incidence by baseline characteristics in the Physicians’ Health Study (United States)», Cancer Causes Control, 2000, 11 (7), p. 617–626.

{9} Lee I. M., Cook N. R., Manson J. E., Buring J. E., Hennekens C. H., «Beta-carotene supplementation and Incidence of cancer and cardiovascular disease: The Women’s Health Study», J. Natl. Cancer Inst., 1999, 91 (24), p. 2102–2106.

{10} De Klerk N. H., Musk A. W., Ambrosini G. L., Eccles J. L., Hansen J., Olsen N., Watts V. L., Lund H. G., Pang S. C., Beilby J., Hobbs M. S., «Western perth asbestos workers, Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene», Int. J. Cancer, 1998, 75 (3), p. 362–367.

{11} Hercberg S., Kesse-Guyot E., Druesne-Pecollo N., Touvier M., Favier A., Latino-Martel P., Briançon S., Galan P., «Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: A postintervention follow-up in the SU.VI.MAX Study», Int. J. Cancer, 2010, epub.

{12} Meyer F., Galan P., Douville P., Bairati I., Kegle P., Bertrais S., Estaquio C., Hercberg S., «Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial», Int. J. Cancer, 2005, 116 (2), p. 182–186.

{13} Hercberg S., Ezzedine K., Guinot C. et al., «Antioxidant supplementation increases the risk of skin cancers in women but not in men», J. Nutr., 2007, 137, p. 2098–2105.

{14} Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L. Jr, Valanis B., Williams J. H. Jr, Barnhart S., Cherniack M. G., Brodkin C. A., Hammar S., «Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial», J. Natl. Cancer Inst, 1996, 88 (21), p. 1550–1559.

{15} National Cancer Institute, Selenium and Vitamin E Cancer Prevention Trial (SELECT), 2008. Disponible sur: http://www.cancer.gov/ newscenter/pressreleases/SELECTQandA (consulté le 15 mars 2010).

{16} Nelson R. L., «Iron and colorectal cancer risk, human studies», Nutr. Rev., 2001, 59, p. 140–148.

{17} Duffield-Lillico A. J., Dalkin B. L., Reid M. E., Turnbull B. W., Slate E. H., Jacobs E. T., Marshall J. R., Clark L. C., «Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and Incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial», BJU Int. 2003, 91 (7), p. 608—6012.

{18} Clark L. C., Combs G. F. Jr, Turnbull B. W., Slate E. H., Chalker D. K., ChowJ., Davis L. S., Glover R. A., Graham G. F., Gross E. G., KrongradA., Lesher J. L. Jr, Park H. K., Sanders B. B. Jr, Smith C. L., Taylor J. R., «Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial», JAMA, 1996, 276 (24), p. 1957–1963.